We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

4D Image-guided Adaptive Radiotherapy for Lung Cancer: Patient Image Acquisition

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01018147
Recruitment Status : Completed
First Posted : November 23, 2009
Last Update Posted : February 8, 2016
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Virginia Commonwealth University

Brief Summary:
This clinical trial studies 4-dimensional (4-D) image-guided radiation therapy treatment planning in patients with stage I-IV non-small cell lung cancer. Computed tomography (CT) scans and treatment-planning systems may help in planning radiation therapy for patients with non-small cell lung cancer. This is not a therapy study. Therefore no direct benefit from participating is expected. However, at the discretion of the treating physician, the information gained from the additional imaging will be used to improve treatment accuracy. No patient outcome data are gathered or analyzed by this study. This study is not a:Phase I, II, or III trial, trial with "blinded" treatment arm, gene or a vaccine trial, or a multi-institutional trial.

Condition or disease Intervention/treatment
Lung Cancer Procedure: 4-dimensional computed tomography

Detailed Description:

OBJECTIVES:

  • Quantify the magnitude and distribution of inter- and intrafraction anatomic variations, including the temporal stability of the tumor/respiration signal correlation.
  • Improve the acquisition and reconstruction of 4D CT scan images by advancing the 4D CT scan data collection process and evaluating 4D CT scan image reconstruction using different respiratory inputs.
  • Quantify the uncertainty of deformable image-registration algorithms.
  • Develop and investigate the efficacy of inter- and intrafraction probabilistic planning-based 4D image-guided adaptive radiotherapy (IGART) strategies for clinical application.
  • Determine the expected geometric, dosimetric, and radiobiological improvements from the 4D IGART system.

OUTLINE: Patients undergo insertion of ≥ 1 small radio-opaque marker into (or in the vicinity of) the primary lesion or suspect lymph nodes via bronchoscopy. X-rays are performed to document the position of the markers.

Patients undergo 4D CT scan before each radiotherapy session and once a week after a radiotherapy session. Patients also undergo x-ray imaging before and during radiotherapy, optical and internal marker motion recording before and after radiotherapy, and audiovisual feedback during radiotherapy.

Patients undergo image-guided adapted radiotherapy based on these data.


Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 22 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Official Title: 4D Image-guided Adaptive Radiotherapy for Lung Cancer: Patient Image Acquisition
Study Start Date : September 2006
Primary Completion Date : April 2012
Study Completion Date : October 2015

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lung Cancer
U.S. FDA Resources

Arm Intervention/treatment
Experimental: CT Imaging
Patients undergo 4-D, 4-dimensional computed tomography, CT imaging prior to radiotherapy sessions and once a week at the end of treatment.
Procedure: 4-dimensional computed tomography
Undergo 4-D CT imaging
Other Name: 4D-CT



Primary Outcome Measures :
  1. At least 1 mm reduction in overall systematic error corresponding with ≥ 2 mm CTV-PTV margin reduction [ Time Frame: Up to 7 years ]
  2. At least 5 Gy reduction in mean lung dose [ Time Frame: up to 7 years ]
  3. At least 5% reduction in absolute pneumonitis risk (≥ grade 2) [ Time Frame: up to 7 years ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologic or cytologic confirmation of non-small cell lung cancer stages I-IV
  • Partial pressure oxygen (pO2) > 92%-obtained at the time of or within 3 months prior to initial consultation with the radiation oncologist
  • Tumor(s) must be visualized on a CT
  • Positron emission tomography (PET) is performed during staging or treatment planning process
  • All patients must be informed on the investigational nature of this study and must give informed consent in accordance with institutional guidelines

Exclusion Criteria:

  • Pregnant women may not participate; women of reproductive potential must be informed of the need to practice an effective contraceptive method
  • Unstable coronary artery disease
  • Uncorrectable coagulopathy
  • Severe pulmonary hypertension
  • Poor tolerance of conscious sedation

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01018147


Sponsors and Collaborators
Virginia Commonwealth University
National Cancer Institute (NCI)
Investigators
Principal Investigator: Jeffrey F. Williamson, PhD Massey Cancer Center

Additional Information:
Responsible Party: Virginia Commonwealth University
ClinicalTrials.gov Identifier: NCT01018147     History of Changes
Other Study ID Numbers: MCC-10395
HM-10395 ( Other Identifier: VCU IRB )
CDR0000657239 ( Registry Identifier: PDQ (Physician Data Query) )
NCI-2011-01700 ( Registry Identifier: CTRP (Clinical Trials Reporting System) )
First Posted: November 23, 2009    Key Record Dates
Last Update Posted: February 8, 2016
Last Verified: February 2016

Keywords provided by Virginia Commonwealth University:
stage IIIA non-small cell lung cancer
stage IIIB non-small cell lung cancer
stage IA non-small cell lung cancer
stage IB non-small cell lung cancer
stage IIA non-small cell lung cancer
stage IIB non-small cell lung cancer

Additional relevant MeSH terms:
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases